This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Celsion Short Thesis, Hemispherx

Stocks in this article: CLSN HEB

The authors do caution intravenous doxorubicin may have limited drug exposure at the tumor site. Thermodox might increase doxorubicin concentration in the tumor but, again, success would break a long losing streak for any chemotherapy in primary liver cancer. Full citation: Heptatol Int (2011) 5:567-574

These are the main reasons why my fund manager source believes the Thermodox still will fail. He is short Celsion. I don't expect everyone to agree with him, but if you're a Thermodox believer and are betting on success in the phase III trial, it's still vital to know what the other side of the trade is thinking.

Celsion is expected to announce top-line results from the Thermodox study in January.

Ted starts his email quoting previous comments I made skeptical of Hemipsherx Biopharma (HEB):

The only attention Hemispherx is getting comes from day traders and biotech "run-up" traders anticipating the Dec. 20 FDA advisory panel for the company's chronic fatigue syndrome therapy Ampligen. At 5%, Hemispherx has even less institutional investor support than Galena Biopharma. This FDA panel isn't likely to end well for Ampligen, just like Hemispherx's previous stabs at getting Ampligen approved based on overly massaged data from a failed clinical trial.

Ted disagrees:

"You are so bleeping biased!" he writes. "What makes you think FDA panel will vote against Ampligen? How about those millions of people suffering from CFS? Have you had any conversation with any of them to better understand Ampligen? Drug is safe and has no side effects. Why would the panel vote against it?"

Ampligen is already available to people suffering from chronic fatigue syndrome today, but it's barely used. If Ampligen is safe and effective, as the relatively few Hemispherx bulls contend, why aren't more CFS patients being treated with it?

Since May 1997, FDA has allowed Hemispherx to administer Ampligen to CFS patients under a "compassionate use" exception. Hemispherx is even allowed to recoup costs associated with Ampligen so that compassionate use isn't a financial burden on the company.

In the first nine months of 2012, 33 CFS patients were on Ampligen therapy, according to Hemispherx regulatory filings. In 2001, the number was 36. In 2010, 21 patients took the drug. In 2009, Ampligen was used by 18 patients, according to Hemispherx.

The availability of Ampligen today torpedoes the bull thesis that insists, falsely, that FDA will grant the drug full approval under newly enacted provisions in the FDA Safety and Innovation Act (FDASIA.) FDA long ago took steps to make Ampligen available but patients don't want it!

3 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs